Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug Remdesivir for Europe, Asia and the developing world through at least 2022. Gilead also said on Tuesday it was negotiating long-term licenses with several generic drugmakers in India and Pakistan to produce Remdesivir for developing countries.
remdesivir,remdesivir india,remdesivir news,remdesivir medicine,remdesivir coronavirus,remdesivir trials coronavirus,coronavirus,covid-19,india news in hindi,coronavirus cases in india,coronavirus treatment in india,remdesivir gilead,remdesivir icmr,remdesivir pronounciation,remdesivir treat,remdesivir fauci,remdesivir ebola,remdesivir use,remdesivir covid 19,drug remdesivir,coronavirus pandemic,remdesivir mechanism,gilead remdesivir,
Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug Remdesivir for Europe, Asia and the developing world through at least 2022. Gilead also said on Tuesday it was negotiating long-term licenses with several generic drugmakers in India and Pakistan to produce Remdesivir for developing countries.
0 Comments